Vanderbilt-Ingram Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vanderbilt-Ingram Cancer Center sits in the top decile of US sponsors by registered trial count (#157 of 15,742 sponsors by registered trial count).
Vanderbilt-Ingram Cancer Center: 189 sponsored US clinical trials, 28 recruiting.
Vanderbilt-Ingram Cancer Center sponsors 189 registered US clinical trials on ClinicalTrials.gov, 28 of them currently recruiting, and 87 completed. 7 of these trials are in Phase 3-4 (later-stage) and 97 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lung Cancer, with 10 trials.
Top-decile sponsor footprint
Vanderbilt-Ingram Cancer Center ranks in the top decile of sponsors by registered trial count (#157 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
87 of 152 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (57.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
189 total, page 3 of 4
3T MRI Biomarkers of Glioma Treatment Response
NCT01996527
FDG-PET in Advanced Melanoma
NCT02236546
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
NCT01316692
Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis
NCT01324908
Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
NCT01365910
Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
NCT01276210
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
NCT01227018
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
NCT01248494
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
NCT01215344
Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients
NCT01215734
PET/CT Evaluation of Treatment Response in Breast Cancer
NCT01222416
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
NCT01205685
Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer
NCT01207895
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
NCT01396382
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
NCT01096381
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
NCT00987766
Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel
NCT01096407
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
NCT01031446
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
NCT00983268
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
NCT00984542
Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery
NCT00984490
Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes
NCT01141218
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
NCT00930930
Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
NCT00892801
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
NCT00949052
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
NCT00957736
Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
NCT00837876
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
NCT00755040
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
NCT00765245
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
NCT00680758
PET Study in Patients With Non-Hodgkin Lymphoma
NCT00712556
Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants
NCT00899457
Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery
NCT00651976
Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
NCT00544648
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00550537
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
NCT00520845
Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
NCT00514020
Family Quality of Life Among Families With a Member Who is a Cancer Patient
NCT00544336
Pain Control in Hospice Patients With Cancer-Related Pain
NCT00609297
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
NCT00499681
Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
NCT00573404
Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
NCT00602147
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
NCT00896675
Studying Biomarkers in Patients With Pancreatic Cancer
NCT00900003
Investigation of Pain and Symptom Burden in Patients With Newly Diagnosed Head and Neck Cancer
NCT00655005
Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer
NCT00898742
Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer
NCT00574145
Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer
NCT00897468
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
NCT00897832
Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant
NCT00900406
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 46 |
| Phase 2 | 51 |
| Phase 3 | 4 |
| Phase 4 | 3 |
What is open in the Vanderbilt-Ingram Cancer Center pipeline
28 recruiting of 189 indexed (15% open); 87 completed (46%).
Phase mix: 7 late (III/IV) vs 97 early (I/II) (early-phase heavy).
Top condition: Lung Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vanderbilt-Ingram Cancer Center: open-pipeline peers nationwide
Peers matched on 189 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Vanderbilt-Ingram Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 189 trials (± recruiting share)
- Nationwide Children's Hospital · 188 trials · 15% recruiting
- Vertex Pharmaceuticals Incorporated · 191 trials · 10% recruiting
- Arizona State University · 187 trials · 15% recruiting
- Johns Hopkins Bloomberg School of Public Health · 187 trials · 14% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- University of Rochester · 15% recruiting · 636 trials
- Loma Linda University · 15% recruiting · 237 trials
- University of Washington · 15% recruiting · 1,048 trials
Related
What to do with this Vanderbilt-Ingram Cancer Center page
189 registered trials is a research-attention snapshot, not an endorsement of Vanderbilt-Ingram Cancer Center or any single study.
- 28 of Vanderbilt-Ingram Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lung Cancer is the condition Vanderbilt-Ingram Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vanderbilt-Ingram Cancer Center pipeline card: 189 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.